Programs & products

Complete safety results and updated clinical activity data will be presented at the ICML 2017 in Lugano in June; Preparation for cohort expansion part is ongoing. Innate Pharma SA (the “Company” -...

Increased scope to explore additional cohorts of Opdivo (nivolumab) plus lirilumab in solid tumors, including a cohort exploring Opdivo with or without lirilumab in squamous cell carcinoma of the head...

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces...

The study did not meet the primary efficacy endpoint Study confirms the safety profile of lirilumab as a monotherapy Broad clinical program ongoing, investigating lirilumab in a variety of tumor...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that, per the licensing agreement for lirilumab, Bristol-Myers Squibb has paid Innate Pharma a US$15 million...

Preliminary data from the dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with Sezary syndrome; IPH4102 shows good safety...

Abstract now available online - More data in oral presentation on November 12 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces the publication of the late-breaking...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent...

Objective response rate (ORR) was 24% in 29 evaluable patients and increased in inflamed (PD-L1 positive) tumors, with ORR of 41% in patients with > 1% PD-L1 expression No significant added toxicity...

Data from the dose-ranging part of a Phase I/II trial of monalizumab in 18 patients with advanced gynecologic malignancies; Monalizumab had no dose-limiting toxicities, highest dose level chosen for...